BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 8, 2006
View Archived Issues
ODAC: Study Required To Expand Abraxane's Label
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Thursday disagreed with a shortened approval pathway for Abraxane (paclitaxel) as an adjuvant breast cancer treatment, which would expand its label. (BioWorld Today)
Read More
Dynavax In Potential $136M Agreement With AstraZeneca
Read More
RenaMed Adds $40M Privately For Acute Renal Failure Drug
Read More
King Buys Ligand's Avinza Rights For $265M Up Front
Read More
Clinic Roundup
Read More
Other News To Note
Read More